MASLD in Chronic Hepatitis B Patients Increases Systemic Health Risks

A new study published in the European Medical Journal highlights that Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) significantly elevates systemic health risks in patients with chronic Hepatitis B.

The research indicates that the co-existence of these conditions complicates clinical management and increases the likelihood of long-term liver damage.

Healthcare providers are being urged to implement integrated screening protocols to identify MASLD early in Hepatitis B patients to improve overall patient outcomes.